Diagnostic and therapeutic applications of monoclonal antibodies in colorectal cancer (original) (raw)
References
Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256:495–7. Google Scholar
Schroff RW, Foon KA, Beatty SM, Oldham RK, Morgan AC Jr. Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res 1985;45:879–85. Google Scholar
Haseman MK, Brown DW, Keeling CA, Reed NL. Radioimmunodetection of occult carcinoembryonic antigen-producing cancer. J Nucl Med 1992;33:1750–6. Google Scholar
Collier BD, Abdel-Nabi H, Doerr RJ,et al. Immunoscintigraphy performed with In-111-labeled CYT-103 in the management of colorectal cancer: comparison with CT. Radiology 1992;185:179–86. Google Scholar
Doerr RJ, Abdel-Nabi H, Krag D, Mitchell E. Radiolabeled antibody imaging in the management of colorectal cancer: results of a multicenter clinical study. Ann Surg 1991;214:118–24. Google Scholar
Steinstrasser A, Oberhausen E. Anti-CEA labelling kit BW 431/26: results of the European multicenter trial. Nuklearmedizin 1995;34:232–42. Google Scholar
Corman ML, Galandiuk S, Block GE,et al. Immunoscintigraphy with 111In-satumomab pendetide in patients with colorectal adenocarcinoma: performance and impact on clinical management. Dis Colon Rectum 1994;37:129–37. Google Scholar
Dillman RO, Shawler DL, McCallister TJ, Halpern SE. Human anti-mouse antibody response in cancer patients following single low-dose injections of radiolabeled murine monoclonal antibodies. Cancer Bioth 1994;9:17–28. Google Scholar
Lind P, Lechner P, Arian-Schad K,et al. Anticarcinoembryonic antigen immunoscintigraphy (technetium-99m-monoclonal antibody BW 431/26) and serum CEA levels in patients with suspected primary and recurrent colorectal carcinoma. J Nucl Med 1991;32:1319–25. Google Scholar
Abdel-Nabi HH, Doerr RJ, Chan HW,et al. Safety and role of repeated administrations of Indium-111-labeled anti-carcinoembryonic antigen monoclonal antibody ZCE 025 in the postoperative follow-up of colorectal carcinoma patients. J Nucl Med 1992;33:14–22. Google Scholar
Frodin JE, Lefvert AK, Mellstedt H. Pharmacokinetics of the mouse monoclonal antibody 17-1A in cancer patients receiving various treatment schedules. Cancer Res 1990;50:4866–71. Google Scholar
Colcher D, Milenic DE, Ferroni P,et al. In vivo fate of monoclonal antibody B72.3 in patients with colorectal cancer. J Nucl Med 1990;31:1133–42. Google Scholar
Ledermann JA, Begent RH, Massof C, Kelly AM, Adam T, Bagshawe KD. A phase-I study of repeated therapy with radiolabelled antibody to carcinoembryonic antigen using intermittent or continuous administration of cyclosporin A to suppress the immune response. Int J Cancer 1991;47:659–64. Google Scholar
Dhingra K, Fritsche H, Murray JL,et al. Phase I clinical and pharmacological study of suppression of human antimouse antibody response to monoclonal antibody L6 by deoxyspergualin. Cancer Res 1995;55:3060–7. Google Scholar
Morton BA, O'Connor-Tressel M, Beatty BG, Shively JE, Beatty JD. Artifactual CEA elevation due to human anti-mouse antibodies. Arch Surg 1988;123:1242–6. Google Scholar
Hansen HJ, LaFontaine G, Newman ES,et al. Solving the problem of antibody interference in commercial “sandwich”-type immunoassays of carcinoembryonic antigen. Clin Chem 1989;35:146–51. Google Scholar
Newman ES, Moskie LA, Duggal RN, Goldenberg DM, Hansen HJ. Murine monoclonal antibody adsorbed onto vinylidene fluoride floccules used to eliminate antibody interference in “sandwich”-type immunoassays. Clin Chem 1989;35:1743–6. Google Scholar
Koprowski H, Herlyn D, Lubeck M, DeFreitas E, Sears HF. Human anti-idiotype antibodies in cancer patients: is the modulation of the immune response beneficial for the patient? Proc Natl Acad Sci U S A 1984;81:216–9. Google Scholar
Bhattacharya-Chatterjee M, Mukerjee S, Biddle W, Foon KA, Kohler H. Murine monoclonal anti-idiotype antibody as a potential network antigen for human carcinoembryonic antigen. J Immunol 1990;145:2758–65. Google Scholar
Fagerberg J, Hjelm AL, Ragnhammar P, Frodin JE, Wigzell H, Mellstedt H. Tumor regression in monoclonal antibody-treated patients correlates with the presence of anti-idiotype-reactive T lymphocytes. Cancer Res 1995;55:1824–7. Google Scholar
Sun LK, Curtis P, Rakowicz-Szulczynska E,et al. Chimeric antibodies with 17-1A-derived variable and human constant regions. Hybridoma 1986;5(Suppl 1):S17–20. Google Scholar
Morrison SL. Transfectomas provide novel chimeric antibodies. Science 1985;229:1202–7. Google Scholar
Velders MP, Litvinov SV, Warnaar SO,et al. New chimeric anti-pancarcinoma monoclonal antibody with superior cytotoxicity-mediating potency. Cancer Res 1994;54:1753–9. Google Scholar
Hardman N, Gill LL, De Winter RF,et al. Generation of a recombinant mouse-human chimaeric monoclonal antibody directed against human carcinoembryonic antigen. Int J Cancer 1989;44:424–33. Google Scholar
Buchegger F, Pelegrin A, Hardman N,et al. Different behaviour of mouse-human chimeric antibody F(ab')2 fragments of IgG1, IgG2 and IgG4 sub-class in vivo. Int J Cancer 1992;50:416–22. Google Scholar
LoBuglio AF, Wheeler RH, Trang J,et al. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci U S A 1989;86:4220–4. Google Scholar
Meredith RF, LoBuglio AF, Plott WE,et al. Pharmacokinetics, immune response, and biodistribution of iodine-131-labeled chimeric mouse/human IgG1, k 17-1A monoclonal antibody. J Nucl Med 1991;32:1162–8. Google Scholar
Meredith RF, Khazaeli MB, Plott WE,et al. Phase I trial of iodine-131-chimeric B72.3 (human IgG4) in metastatic colorectal cancer. J Nucl Med 1992;33:23–9. Google Scholar
Goodman GE, Hellstrom I, Yelton DE,et al. Phase I trial of chimeric (human-mouse) monoclonal antibody L6 in patients with non-small-cell lung, colon, and breast cancer. Cancer Immunol Immunother 1993;36:267–73. Google Scholar
Wong JY, Williams LE, Yamauchi DM,et al. Initial experience evaluating 90yttrium-radiolabeled anticarcinoembryonic antigen chimeric T84.66 in a phase I radioimmunotherapy trial. Cancer Res 1995;55(Suppl):5929s-34s. Google Scholar
Hosono M, Endo K, Sakahara H,et al. Human/mouse chimeric antibodies show low reactivity with human anti-murine antibodies (HAMA). Br J Cancer 1992;65:197–200. Google Scholar
Khazaeli MB, Saleh MN, Liu TP,et al. Pharmacokinetics and immune response of131I-chimeric mouse/human B72.3 (human gamma 4) monoclonal antibody in humans. Cancer Res 1991;51:5461–6. Google Scholar
Buchegger F, Mach JP, Pelegrin A,et al. Radiolabeled chimeric anti-CEA monoclonal antibody compared with the original mouse monoclonal antibody for surgically treated colorectal carcinoma. J Nucl Med 1995;36:420–9. Google Scholar
Fagerberg J, Ragnhammar P, Liljefors M, Hjelm AL, Mellstedt H, Frodin JE. Humoral anti-idiotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-1A. Cancer Immunol Immunother 1996;42:81–7. Google Scholar
Steinitz M, Klein G, Koskimies S, Makel O. EB virus-induced B lymphocyte cell lines producing specific antibody. Nature 1977;269:420–2. Google Scholar
Olsson L, Kaplan HS. Human-human hybridomas producing monoclonal antibodies of predefined antigenic specificity. Proc Natl Acad Sci U S A 1980;77:5429–31. Google Scholar
Del Vecchio S, Carrasquillo JA, Steis R,et al. Imaging of colon cancer with I-131 28A32 human monoclonal antibody. J Nucl Med 1987;28:636 [abstract]. Google Scholar
Steis RG, Carrasquillo JA, McCabe R,et al. Toxicity, immunogenicity, and tumor radioimmunodetecting ability of two human monoclonal antibodies in patients with metastatic colorectal carcinoma. J Clin Oncol 1990;8:476–90. Google Scholar
Koda K, Glassy MC, Chang HR. Generation of human monoclonal antibodies against colon cancer. Arch Surg 1990;125:1591–7. Google Scholar
De Jager RL, McCabe RP, Subramanian R,et al. Radio-immunodetection of colorectal carcinoma with a technetium-99m labeled human IgG monoclonal antibody: 88BV59-1: a phase I clinical trial. Proc Am Assoc Cancer Res 1991;32:184. Google Scholar
De Jager RL, Abdel-Nabi H, Serafini A,et al. Radioimmunoscintigraphy (RIS) of colorectal cancer with human monoclonal antibody (AB) 88BV59. Antibody Immunoconj Radiophar 1992;5:332. Google Scholar
Gulec SA, Serafini AN, Moffat FL,et al. Radioimmunoscintigraphy of colorectal carcinoma using technetium-99m-labeled, totally human monoclonal antibody 88BV59H21-2. Cancer Res 1995;55(Suppl):5774s-6s. Google Scholar
Abdel-Nabi H, Evans N, Farrell E,et al. Colorectal carcinoma tumor targeting with elevated human antimouse antibody (HAMA) levels. Antibody Immunoconj Radiophar 1992;5:352. Google Scholar
Denton GW, Durrant LG, Hardcastle JD, Austin EB, Sewell HF, Robins RA. Clinical outcome of colorectal cancer patients treated with human monoclonal antidiotypic antibody. Int J Cancer 1994;57:10–4. Google Scholar
Chang HR, Chavoshan B, Park H. Human monoclonal antibody SK1-mediated cytotoxicity against colon cancer cells. Dis Colon Rectum 1993;36:1152–7. Google Scholar
Erb K, Borup-Christensen P, Ditzel H, Chemnitz J, Haas H, Jensenius JC. Characterization of a human-human hybridoma antibody, C-OU1, directed against a colon tumor-associated antigen. Hybridoma 1992;11:121–34. Google Scholar
Ditzel H, Rasmussen JW, Erb K,et al. Tumor detection with131I-labeled human monoclonal antibody COU-1 in patients with suspected colorectal carcinoma. Cancer Res 1993;53:5920–8. Google Scholar
Goldenberg DM, Ford EH, Lee RE,et al. Cancer imaging with a new 99m-Tc-antibody method [abstract]. J Nucl Med 1989;15:426. Google Scholar
Yokota T, Milenic DE, Whitlow M, Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 1992;52:3402–8. Google Scholar
Lane DM, Eagle KF, Begent RH,et al. Radioimmunotherapy of metastatic colorectal tumours with iodine-131-labelled antibody to carcinoembryonic antigen: phase I/II study with comparative biodistribution of intact and F(ab')2 antibodies. Br J Cancer 1994;70:521–5. Google Scholar
Siccardi AG, Buraggi GL, Callegaro L,et al. Immunoscintigraphy of adenocarcinomas by means of radiolabeled F(ab')2 fragments of an anticarcinoembryonic antigen monoclonal antibody: a multicenter study. Cancer Res 1989;49:3095–103. Google Scholar
Serafini AN, Goldenberg DM, Higginbotham-Ford EA,et al. A multicenter trial of cancer imaging with fragments of CEA monoclonal antibodies. J Nucl Med 1989;30:748. Google Scholar
Lamki LM, Patt YZ, Rosenblum MG,et al. Metastatic colorectal cancer: radioimmunoscintigraphy with a stabilized In-111-labeled F(ab')2 fragment of an anti-CEA monoclonal antibody. Radiology 1990;174:147–51. Google Scholar
Behr TM, Becker WS, Klein MW, Bair HJ, Scheele JR, Wolf FG. Diagnostic accuracy and tumor-targeting kinetics of complete_versus_ fragmented 99mTc-labeled anti-carcinoembryonic antigen antibodies: an intraindividual comparison. Cancer Res 1995;55(Suppl):5786s-93s. Google Scholar
Goldenberg DM, Wlodkowski TJ, Sharkey RM,et al. Colorectal cancer imaging with iodine-123-labeled CEA monoclonal antibody fragments. J Nucl Med 1993;34:61–70. Google Scholar
Lechner P, Lind P, Binter G, Cesnik H. Anticarcinoembryonic antigen immunoscintigraphy with a 99mTc-Fab' fragment (Immu 4) in primary and recurrent colorectal cancer: a prospective study. Dis Colon Rectum 1993;36:930–5. Google Scholar
Moffat FL Jr, Vargas-Cuba RD, Serafini AN,et al. Radioimmunodetection of colorectal carcinoma using technetium-99m-labeled Fab' fragments of the IMMU-4 anti-carcinoembryonic antigen monoclonal antibody. Cancer 1994;73(Suppl):836–45. Google Scholar
Murray JL, Rosenblum MG, Zhang HZ,et al. Comparative tumor localization of whole immunoglobulin G anticarcinoembryonic antigen monoclonal antibodies IMMU-4 and IMMU-4 F(ab')2 in colorectal cancer patients. Cancer 1994;73(Suppl):850–7. Google Scholar
Gold P, Freedman SO. Specific carcinoembryonic antigens of the human digestive system. J Exp Med 1965;122:461–85. Google Scholar
Goldenberg DM, DeLand F, Kim E,et al. Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. N Engl J Med 1978;298:1384–6. Google Scholar
Mach JP, Buchegger F, Forni M,et al. Use of radiolabeled monoclonal anti-CEA antibodies for the detection of human carcinomas by external photoscanning and tomoscintigraphy. Immunol Today 1981;2:239–49. Google Scholar
Abdel-Nabi HH, Schwartz AN, Higano CS, Wechter DG, Unger MW. Colorectal carcinoma: detection with indium-111 anticarcinoembryonic-antigen monoclonal antibody ZCE-025. Radiology 1987;164:617–21. Google Scholar
Behr TM, Sharkey RM, Juweid MI,et al. Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of carcinoembryonic antigen-expressing tumors. Cancer Res 1996;56:1805–16. Google Scholar
Granowska M, Jass JR, Britton KE, Northover JM. A prospective study of the use of 111In-labelled monoclonal antibody against carcino-embryonic antigen in colorectal cancer and of some biological factors affecting its uptake. Int J Colorectal Dis 1989;4:97–108. Google Scholar
Abdel-Nabi HH, Schwartz AN, Goldfogel G,et al. Colorectal tumors: scintigraphy with In-111 anti-CEA monoclonal antibody and correlation with surgical, histopathologic, and immunohistochemical findings. Radiology 1988;166:747–52. Google Scholar
Wang JY, Tang R, Chiang JM. Value of carcinoembryonic antigen in the management of colorectal cancer. Dis Colon Rectum 1994;37:272–7. Google Scholar
Beatty JD, Duda RB, Williams LE,et al. Preoperative imaging of colorectal carcinoma with 111In-labeled anticarcinoembryonic antigen monoclonal antibody. Cancer Res 1986;46:6494–502. Google Scholar
Abdel-Nabi HH, Chan HW, Doerr RJ. Indium-labeled anti-colorectal carcinoma monoclonal antibody accumulation in non-tumored tissue in patients with colorectal carcinoma. J Nucl Med 1990;31:1975–9. Google Scholar
Bosslet K, Steinstrasser A, Schwarz A,et al. Quantitative considerations supporting the irrelevance of circulating serum CEA for the immunoscintigraphic visualization of CEA expressing carcinomas. Eur J Nucl Med 1988;14:523–8. Google Scholar
Hertel A, Baum RP, Lorenz M, Baew-Christow T, Encke A, Hor G. Immunoscintigraphy using a technetium-99m labelled monoclonal anti-CEA antibody in the follow-up of colorectal cancer and other tumours producing CEA. Br J Cancer Suppl 1990;10:34–6. Google Scholar
Richman PI, Bodmer WF. Monoclonal antibodies to human colorectal epithelium: markers for differentiation and tumour characterization. Int J Cancer 1987;39:317–28. Google Scholar
Durbin H, Young S, Stewart LM,et al. An epitope on carcinoembryonic antigen defined by the clinically relevant antibody PR1A3. Proc Natl Acad Sci U S A 1994;91:4313–7. Google Scholar
Granowska M, Britton KE, Mather SJ,et al. Radioimmunoscintigraphy with technetium-99m labelled monoclonal antibody, 1A3, in colorectal cancer. Eur J Nucl Med 1993;20:690–8. Google Scholar
Granowska M, Mather SJ, Britton KE. Diagnostic evaluation of 111In and 99mTc radiolabelled monoclonal antibodies in ovarian and colorectal cancer: correlations with surgery. Int J Rad Appl Instrum [B] 1991;18:413–24. Google Scholar
Colcher D, Hand PH, Nuti M, Schlom J. A spectrum of monoclonal antibodies reactive with human mammary tumor cells. Proc Natl Acad Sci U S A 1981;78:3199–203. Google Scholar
Johnson VG, Schlom J, Paterson AJ, Bennett J, Magnani JL, Colcher D. Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3. Cancer Res 1986;46:850–7. Google Scholar
Kuroki M, Fernsten PD, Wunderlich D,et al. Serological mapping of the TAG-72 tumor-associated antigen using 19 distinct monoclonal antibodies. Cancer Res 1990;50:4872–9. Google Scholar
Esteban JM, Colcher D, Sugarbaker P,et al. Quantitative and qualitative aspects of radiolocalization in colon cancer patients of intravenously administered MAb B72.3. Int J Cancer 1987;39:50–9. Google Scholar
Abdel-Nabi H, Doerr RJ, Chan HW, Balu D, Schmelter RF, Maguire RT. In-111-labeled monoclonal antibody immunoscintigraphy in colorectal carcinoma: safety, sensitivity, and preliminary clinical results. Radiology 1990;175:163–71. Google Scholar
Winzelberg GG, Grossman SJ, Rizk S,et al. Indium-111 monoclonal antibody B72.3 scintigraphy in colorectal cancer: correlation with computed tomography, surgery, histopathology, immunohistology, and human immune response. Cancer 1992;69:1656–63. Google Scholar
Kostakoglu L, Divgi CR, Hilton S,et al. Preselection of patients with high TAG-72 antigen expression leads to targeting of 94 percent of known metastatic tumor sites with monoclonal antibody I-131-CC49. Cancer Invest 1994;12:551–8. Google Scholar
Guadagni F, Roselli M, Cosimelli M,et al. TAG-72 (CA 72-4 assay) as a complementary serum tumor antigen to carcinoembryonic antigen in monitoring patients with colorectal cancer. Cancer 1993;72:2098–106. Google Scholar
Muraro R, Kuroki M, Wunderlich D,et al. Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen. Cancer Res 1988;48:4588–96. Google Scholar
Arnold MW, Schneebaum S, Berens A,et al. Intraoperative detection of colorectal cancer with radioimmunoguided surgery and CC49, a second-generation monoclonal antibody. Ann Surg 1992;216:627–32. Google Scholar
Schlom J, Eggensperger D, Colcher D,et al. Therapeutic advantage of high-affinity anticarcinoma radioimmunoconjugates. Cancer Res 1992;52:1067–72. Google Scholar
Gallinger S, Reilly RM, Kirsh JC,et al. Comparative dual label study of first and second generation antitumor-associated glycoprotein-72 monoclonal antibodies in colorectal cancer patients. Cancer Res 1993;53:271–8. Google Scholar
Herlyn M, Steplewski Z, Herlyn D, Koprowski H. Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies. Proc Natl Acad Sci U S A 1979;76:1438–52. Google Scholar
Steplewski Z, Chang TH, Herlyn M, Koprowski H. Release of monoclonal antibody-defined antigens by human colorectal carcinoma and melanoma cells. Cancer Res 1981;41:2723–7. Google Scholar
Herlyn D, Sears H, Iliopoulos D,et al. Anti-idiotypic antibodies to monoclonal antibody CO17-1A. Hybridoma 1986;5(Suppl 1):S51–8. Google Scholar
Gottlinger HG, Funke I, Johnson JP, Gokel JM, Riethmuller G. The epithelial cell surface antigen 17-1A, a target for antibody-mediated tumor therapy: its biochemical nature, tissue distribution and recognition by different monoclonal antibodies. Int J Cancer 1986;38:47–53. Google Scholar
Herlyn D, Herlyn M, Ross AH, Ernst C, Atkinson B, Koprowski H. Efficient selection of human tumor growth-inhibiting monoclonal antibodies. J Immunol Methods 1984;73:157–67. Google Scholar
Herlyn DM, Steplewski Z, Herlyn MF, Koprowski H. Inhibition of growth of colorectal carcinoma in nude mice by monoclonal antibody. Cancer Res 1980;40:717–21. Google Scholar
Herlyn D, Somasundaram R, Zaloudik J,et al. Anti-idiotype and recombinant antigen in immunotherapy of colorectal cancer. Cell Biophys 1994;24–25:143–53. Google Scholar
Woo DV, Li D, Mattis JA, Steplewski Z. Selective chromosomal damage and cytotoxicity of125I-labeled monoclonal antibody 17-1a in human cancer cells. Cancer Res 1989;49:2952–8. Google Scholar
Meredith RF, Khazaeli MB, Plott WE,et al. Initial clinical evaluation of iodine-125-labeled chimeric 17-1A for metastatic colon cancer. J Nucl Med 1995;36:2229–33. Google Scholar
Riethmuller G, Schneider-Gadicke E, Schlimok G,et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group [see comments]. Lancet 1994;343:1177–83. Google Scholar
Leinsinger G, Kirsch CM, Denecke H, Pletzer G. Immunoscintigraphy using SPECT and I-131 labeled monoclonal antibodies to CEA/CA 19-9 in the follow-up of colorectal cancer. Antib Immunoconj Radiopharm 1991;4:577–85. Google Scholar
Epenetos AA, Nimmon CC, Arklie J,et al. Detection of human cancer in an animal model using radio-labelled tumour-associated monoclonal antibodies. Br J Cancer 1982;46:1–8. Google Scholar
Welt S, Divgi CR, Kemeny N,et al. Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol 1994;12:1561–71. Google Scholar
Breitz HB, Weiden PL, Vanderheyden JL,et al. Clinical experience with rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: results of phase I trials [see comments]. J Nucl Med 1992;33:1099–109. Google Scholar
Bell SM, Scott N, Cross D,et al. Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer. Gastroenterology 1993;104:57–64. Google Scholar
Kressner U, Lindmark G, Gerdin B, Pahlman L, Glimelius B. Immunohistological p53 staining is of limited value in the staging and prognostic prediction of colorectal cancer. Anticancer Res 1996;16:951–7. Google Scholar
Davidson BR, Young H, Waddington WA,et al. Preoperative imaging of colorectal cancers: targeting the epithelial membrane antigen with a radiation-labeled monoclonal antibody. Cancer 1992;69:620–5. Google Scholar
Rodriguez-Bigas MA, Bakshi S, Stomper P, Blumenson LE, Petrelli NJ. 99mTc-IMMU-4 monoclonal antibody scan in colorectal cancer: a prospective study. Arch Surg 1992;127:1321–4. Google Scholar
Beatty JD, Williams LE, Yamauchi D,et al. Presurgical imaging with indium-labeled anti-carcinoembryonic antigen for colon cancer staging. Cancer Res 1990;50(Suppl):922s-6s. Google Scholar
Bock E, Becker W, Scheele J, Wolf F. Diagnostic accuracy of 99mTc-anti-CEA immunoscintigraphy in patients with liver metastases from colorectal carcinoma. Nuklearmedizin 1992;31:80–3. Google Scholar
Behr T, Becker W, Hannappel E, Goldenberg DM, Wolf F. Targeting of liver metastases of colorectal cancer with IgG, F(ab')2, and Fab' anti-carcinoembryonic antigen antibodies labeled with 99mTc: the role of metabolism and kinetics. Cancer Res 1995;55(Suppl):5777s-85s. Google Scholar
Bischof-Delaloye A, Delaloye B, Buchegger F,et al. Clinical value of immunoscintigraphy in colorectal carcinoma patients: a prospective study. J Nucl Med 1989;30:1646–56. Google Scholar
Beatty JD, Hyams DM, Morton BA,et al. Impact of radiolabeled antibody imaging on management of colon cancer. Am J Surg 1989;157:13–9. Google Scholar
Corbisiero RM, Yamauchi DM, Williams LE, Esteban JM, Odom-Maryon T, Beatty JD. Colomparison of immunoscintigraphy and computerized tomography in identifying colorectal cancer: individual lesion analysis. Cancer Res 1991;51:5704–11. Google Scholar
Moffat FL Jr, Pinsky CM, Hammershaimb L,et al. Clinical utility of external immunoscintigraphy with the IMMU-4 technetium-99m Fab' antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum: results of a pivotal, phase III trial. The Immunomedics Study Group. J Clin Oncol 1996;14:2295–305. Google Scholar
Divgi CR, McDermott K, Griffin TW,et al. Lesion-by-lesion comparison of computerized tomography and indium-111-labeled monoclonal antibody C110 radio-immunoscintigraphy in colorectal carcinoma: a multicenter trial. J Nucl Med 1993;34:1656–61. Google Scholar
Scott AM, Macapinlac HA, Divgi CR,et al. Clinical validation of SPECT and CT/MRI image registration in radiolabeled monoclonal antibody studies of colorectal carcinoma. J Nucl Med 1994;35:1976–84. Google Scholar
Dominguez JM, Wolff BG, Nelson H, Forstrom LA, Mullan BP.111In-CYT-103 scanning in recurrent colorectal cancer-does it affect standard management? Dis Colon Rectum 1996;39:514–9. Google Scholar
Cornelius E, West B, Forstrom L, Ferguson D, Schecter L. The lymph node: immunologic functions relevant to radioimmunodiagnosis (RAID) and radioimmunoguided surgery (RIGS). J Nucl Med 1994;35:275P. Google Scholar
Duda RB, Zimmer AM, Rosen ST,et al. Radioimmune localization of occult carcinoma. Arch Surg 1990;125:866–70. Google Scholar
Doerr RJ, Abdel-Nabi H, Merchant B. Indium 111 ZCE-025 immunoscintigraphy in occult recurrent colorectal cancer with elevated carcinoembryonic antigen level. Arch Surg 1990;125:226–9. Google Scholar
Halpern SE, Dillman RO, Amox D,et al. Detection of occult tumor using indium 111-labeled anticarcinoembryonic antigen antibodies. Arch Surg 1992;127:1094–100. Google Scholar
Patt YZ, Podoloff DA, Curley S,et al. Monoclonal antibody imaging in patients with colorectal cancer and increasing levels of serum carcinoembryonic antigen: experience with ZCE-025 and IMMU-4 monoclonal antibodies and proposed directions for clinical trials. Cancer 1993;71(Suppl):4293–7. Google Scholar
Petersen BM Jr, Bass BL, Bates HR, Chandeysson PL, Harmon JW. Use of the radiolabeled murine monoclonal antibody, 111In-CYT-103, in the management of colon cancer. Am J Surg 1993;165:137–42. Google Scholar
Gasparini M, Buraggi GL, Regalia E, Maffioli L, Balzarini L, Gennari L. Comparison of radioimmunodetection with other imaging methods in evaluating local relapses of colorectal carcinoma. Cancer 1994;73(Suppl):846–9. Google Scholar
Paganelli G, Magnani P, Zito F,et al. Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients. Cancer Res 1991;51:5960–6. Google Scholar
Martin DT, Hinkle GH, Tuttle S,et al. Intraoperative radioimmunodetection of colorectal tumor with a hand-held radiation detector. Am J Surg 1985;150:672–5. Google Scholar
Dawson PM, Blair SD, Begent RH, Kelly AM, Boxer GM, Theodorou NA. The value of radioimmunoguided surgery in first and second look laparotomy for colorectal cancer. Dis Colon Rectum 1991;34:217–22. Google Scholar
Burak WE Jr, Schneebaum S, Kim JA,et al. Pilot study evaluating the intraoperative localization of radiolabeled monoclonal antibody CC83 in patients with metastatic colorectal carcinoma [see comments]. Surgery 1995;118:103–8. Google Scholar
Sardi A, Workman M, Mojzisik C, Hinkle G, Nieroda C, Martin EW Jr. Intra-abdominal recurrence of colorectal cancer detected by radioimmunoguided surgery (RIGS system). Arch Surg 1989;124:55–9. Google Scholar
Cohen AM, Martin EW Jr, Lavery I,et al. Radioimmunoguided surgery using iodine 125 B72.3 in patients with colorectal cancer. Arch Surg 1991;126:349–52. Google Scholar
Schneebaum S, Arnold MW, Houchens DP,et al. The significance of intraoperative periportal lymph node metastasis identification in patients with colorectal carcinoma. Cancer 1995;75:2809–17. Google Scholar
Cote RJ, Houchens DP, Hitchcock CL,et al. Intraoperative detection of occult colon cancer micrometastases using 125 I-radiolabled monoclonal antibody CC49. Cancer 1996;77:613–20. Google Scholar
Howell R, Hawley PR, Granowska M, Morris G, Britton KE. Peroperative radioimmunodetection, PROD, of colorectal cancer using 99m-Tc PR1A3 monoclonal antibody. Tumori 1995;81(Suppl):107–8. Google Scholar
Curtet C, Vuillez JP, Daniel G,et al. Feasibility study of radioimmunoguided surgery of colorectal carcinomas using indium-111 CEA-specific monoclonal antibody. Eur J Nucl Med 1990;17:299–304. Google Scholar
Moffat FL Jr, Vargas-Cuba RD, Serafini AN,et al. Preoperative scintigraphy and operative probe scintimetry of colorectal carcinoma using technetium-99m-88BV59. J Nucl Med 1995;36:738–45. Google Scholar
Nieroda CA, Mojzisik C, Hinkle G, Thurston MO, Martin EW Jr. Radioimmunoguided surgery (RIGS) in recurrent colorectal cancer. Cancer Detect Prev 1991;15:225–9. Google Scholar
LoBuglio AF, Saleh M, Peterson L,et al. Phase I clinical trial of CO17-1A monoclonal antibody. Hybridoma 1986;5(Suppl 1):S117–23. Google Scholar
Douillard JY, Lehur PA, Vignoud J,et al. Monoclonal antibodies specific immunotherapy of gastrointestinal tumors. Hybridoma 1986;5(Suppl 1):S139–49. Google Scholar
Sears HF, Herlyn D, Steplewski Z, Koprowski H. Phase II clinical trial of a murine monoclonal antibody cytotoxic for gastrointestinal adenocarcinoma. Cancer Res 1985;45:5910–3. Google Scholar
Verrill H, Goldberg M, Rosenbaum R,et al. Clinical trial of Wistar Institute 17-1A monoclonal antibody in patients with advanced gastrointestinal adenocarcinoma: a preliminary report. Hybridoma 1986;5(Suppl 1):S175–83. Google Scholar
LoBuglio AF, Saleh MN, Lee J,et al. Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. I. Clinical aspects. J Natl Cancer Inst 1988;80:932–6. Google Scholar
Mellstedt H, Frodin JE, Masucci G,et al. Monoclonal antibodies (MAb 17-1A) for the treatment of patients with metastatic colorectal carcinomas. Acta Chir Scand Suppl 1989;549:63–70. Google Scholar
Pullyblank AM, Guillou PJ, Monson JR. m17-1A-, c17-1A-and cSF25-mediated antibody-dependent cell-mediated cytotoxicity in patients with advanced cancer. Br J Cancer 1994;70:753–8. Google Scholar
Hagan PL, Halpern SE, Dillman RO,et al. Tumor size: effect on monclonal antibody uptake in tumor models. J Nucl Med 1986;27:422–7. Google Scholar
Jain RK. Delivery of molecular medicine to solid tumors. Science 1996;271:1079–80. Google Scholar
Baxter LT, Jain RK. Pharmacokinetic analysis of the microscopic distribution of enzyme-conjugated antibodies and prodrugs: comparison with experimental data. Br J Cancer 1996;73:447–56. Google Scholar
Sears HF, Herlyn D, Steplewski Z, Koprowski H. Initial trial use of murine monoclonal antibodies as immunotherapeutic agents for gastrointestinal adenocarcinoma. Hybridoma 1986;5(Suppl 1):S109–15. Google Scholar
Weiner LM, Steplewski Z, Koprowski H, Sears HF, Litwin S, Comis RL. Biologic effects of gamma interferon pre-treatment followed by monoclonal antibody 17-1A administration in patients with gastrointestinal carcinoma. Hybridoma 1986;5(Suppl 1):S65–77. Google Scholar
Frodin JE, Harmenberg U, Biberfeld P,et al. Clinical effects of monoclonal antibodies (MAb 17-1A) in patients with metastatic colorectal carcinomas. Hybridoma 1988;7:309–21. Google Scholar
Weiner LM, Moldofsky PJ, Gatenby RA,et al. Antibody delivery and effector cell activation in a phase II trial of recombinant gamma-interferon and the murine monoclonal antibody CO17-1A in advanced colorectal carcinoma. Cancer Res 1988;48:2568–73. Google Scholar
Riethmuller G, Holz E, Schlimok G,et al. Monoclonal antibody (MAB) adjuvant therapy of Dukes' C colorectal carcinoma: 7-year update of a prospective randomized trial. Proc Am Soc Clin Oncol 1996;5:444. Google Scholar
Moertel CG, Fleming TR, Macdonald JS,et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;322:352–8. Google Scholar
Moertel CG, Fleming TR, Macdonald JS,et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995;122:321–6. Google Scholar
Krook JE, Moertel CG, Gunderson LL,et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma [see comments]. N Engl J Med 1991;324:709–15. Google Scholar
Schneider-Gadicke E, Riethmuller G. Prevention of manifest metastasis with monoclonal antibodies: a novel approach to immunotherapy of solid tumours [Review]. Eur J Cancer 1995;31A:1326–30. Google Scholar
Schöber C, Schultke M, Schlimok G,et al. Open label pitol study of monoclonal antibody 17-1A in combination with 5-Fluorouracil/Levamisole or 5FU/Folinic Acid in patients with advanced colorectal cancer [abstract]. Proc Am Soc Clin Oncol 1996;15:229. Google Scholar
Markoe AM, Brady LW, Woo D,et al. Treatment of gastrointestinal cancer using monoclonal antibodies. In: Vaeth JM, Meyer JL, eds. The present and future role of monoclonal antibodies in the management of cancer. Vol. 24. Basel: Karger, 1990:214–24. Google Scholar
Rosenblum MG, Macey D, Podoloff D,et al. A Phase I pharmacokinetic, toxicity and dosimetry study of131I-labeled IMMU-4 F(ab')2 in patients with advanced colorectal carcinoma. Antibody Immunoconj Radiopharm 1993;6:239. Google Scholar
Murray JL, Macey DJ, Kasi LP,et al. Phase II radioimmunotherapy trial with131I-CC49 in colorectal cancer. Cancer 1994;73(Suppl):1057–66. Google Scholar
Divgi CR, Scott AM, Dantis L,et al. Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon carcinoma. J Nucl Med 1995;36:586–92. Google Scholar
Yu B, Carrasquillo J, Milenic D,et al. Phase I trial of iodine 131-labeled COL-1 in patients with gastrointestinal malignancies: influence of serum carcinoembryonic antigen and tumor bulk on pharmacokinetics. J Clin Oncol 1996;14:1798–809. Google Scholar
Buchegger F, Rojas A, Delaloye AB,et al. Combined radioimmunotherapy and radiotherapy of human colon carcinoma grafted in nude mice. Cancer Res 1995;55:83–9. Google Scholar
Tschmelitsch J, Welt S, Barendswaard E, Yao T-J, Cohen A, Old LJ. Enhanced antitumor activity of combination radioimmunotherapy (131I-monoclonal antibody A33) with chemotherapy (fluorouracil) [abstract]. Proc Am Assoc Cancer Res 1996;37:469. Google Scholar
Ballantyne KC, Perkins AC, Pimm MV,et al. Biodistribution of a monoclonal antibody-methotrexate conjugate (791T/36-MTX) in patients with colorectal cancer. Int J Cancer Suppl 1988;2:103–8. Google Scholar
Takahashi T, Yamaguchi T, Kitamura K,et al. Clinical application of monoclonal antibody-drug conjugates for immunotargeting chemotherapy of colorectal carcinoma. Cancer 1988;61:881–8. Google Scholar
Takahashi T, Yamaguchi T, Kitamura K, Noguchi A, Honda M, Otsuji E. Follow-up study of patients treated with monoclonal antibody-drug conjugate: report of 77 cases with colorectal cancer. Jpn J Cancer Res 1993;84:976–81. Google Scholar
Byers VS, Rodvien R, Grant K,et al. Phase I study of monoclonal antibody-ricin A chain immunotoxin XomaZyme-791 in patients with metastatic colon cancer. Cancer Res 1989;49:6153–60. Google Scholar
LoRusso PM, Lomen PL, Redman BG, Poplin E, Bander JJ, Valdivieso M. Phase I study of monoclonal antibody-ricin A chain immunoconjugate Xomazyme-791 in patients with metastatic colon cancer. Am J Clin Oncol 1995;18:307–12. Google Scholar
Zalcberg JR, Pietersz G, Toohey B,et al. A phase I/II study of the intralesional injection of ricin-monoclonal antibody conjugates in patients with hepatic metastases. Eur J Cancer 1994;30A:1227–31. Google Scholar
Litton MJ, Dohlsten M, Lando PA,et al. Antibody-targeted superantigen therapy induces tumorinfiltrating lymphocytes, excessive cytokine production, and apoptosis in human colon carcinoma. Eur J Immunol 1996;26:1–9. Google Scholar
Giantonio BJ, Weiner LM, Alpaugh RK,et al. Superantigen based immunotherapy: a phase I trial of the staphylococcal enterotoxin a (SEA) with advanced pancreatic and colorectal cancer [abstract]. Proc Am Soc Clin Oncol 1996;15:443. Google Scholar
Penna C, Dean PA, Nelson H. Antitumor x anti-CD3 bifunctional antibodies redirect T-cells activated in vivo with staphylococcal enterotoxin B to neutralize pulmonary metastases. Cancer Res 1994;54:2738–43. Google Scholar
Nieken J, Vershueren RC, Timens W, De Ley L, Mulder NH. Intratumoral (i.t.) bispecific monoclonal antibody (bsmAb) in the treatment of colorectal cancer [abstract]. Proc Am Assoc Cancer Res 1995;36:496. Google Scholar
Liesveld JL, Frediani KE, Winslow JM, Duerst RE, Abboud CN. Cytokine effects and role of adhesive proteins and Fc receptors in human macrophage-mediated antibody dependent cellular cytotoxicity. J Cell Biochem 1991;45:381–90. Google Scholar
Ragnhammar P, Fagerberg J, Frodin JE,et al. Effect of monoclonal antibody 17-1A and GM-CSF in patients with advanced colorectal carcinoma-long-lasting, complete remissions can be induced. Int J Cancer 1993;53:751–8. Google Scholar
Ragnhammar P, Fagerberg J, Frodin JE, Wersall P, Hansson LO, Mellstedt H. Granulocyte/macrophagecolony-stimulating factor augments the induction of antibodies, especially anti-idiotypic antibodies, to therapeutic monoclonal antibodies. Cancer Immunol Immunother 1995;40:367–75. Google Scholar
Saleh MN, LoBuglio AF, Wheeler RH,et al. A phase II trial of murine monoclonal antibody 17-1A and interferon-gamma: clinical and immunological data. Cancer Immunol Immunother 1990;32:185–90. Google Scholar
Saleh MN, Khazaeli MB, Wheeler RH,et al. Phase II trial of murine monoclonal antibody D612 combined with recombinant human monocyte colonystimulating factor (rhM-CSF) in patients with metastatic gastrointestinal cancer. Cancer Res 1995;55:4339–46. Google Scholar
Foon KA, Chatterjee S, Chakraborty M, John WJ, Sherratt A, Bhattacharaya-Chatterjee M. Anti-idiotype antibody vaccine (3H1) that mimics the carcinoembryonic antigen (CEA) as adjuvant treatment [abstract]. Proc Am Soc Clin Oncol 1996;15:554. Google Scholar
Pervin S, Sherratt A, Wang H-T,et al. Proliferation of T-cells from colon cancer patients by peptides based on the structure of an anti-idiotype antibody mimicking CEA. Proc Am Assoc Cancer Res 1996;37:473–474. Google Scholar
Ciardiello F, Damiano V, Bianco C,et al. Antitumor activity of anti-epidermal growth factor receptor (EGFR) 225 monoclonal antibody (mAb) in combination with 8-CI-cAMP in human colon cancer xenografts. Proc Am Soc Clin Oncol 1996;15:499. Google Scholar